Verismo Therapeutics, a clinical-stage CAR T company, has once again been recognized as one of the Philadelphia Business Journal’s Best Places to Work for the third consecutive year. This prestigious award highlights the company’s commitment to fostering a positive and engaging workplace culture, attracting top talent, and enabling its team to develop transformative therapies for cancer patients.
Verismo is at the forefront of multi-chain KIR-CAR technology, with promising assets like SynKIR™-110 and SynKIR™-310 currently in Phase 1 clinical trials. Their innovative approach using NK cell-derived KIR and DAP12 split signaling has shown significant efficacy in preclinical models, offering hope for improved treatment outcomes in both solid and hematologic tumors. With a focus on addressing unmet medical needs, Verismo Therapeutics is making strides in advancing CAR T cell therapy. For more information, visit: www.verismotherapeutics.com
Read more from finance.yahoo.com